Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "Shilpa-Medicare"

63 News Found

Mylab partners with Shilpa Biologicals for vaccines and therapeutics segment
News | February 11, 2022

Mylab partners with Shilpa Biologicals for vaccines and therapeutics segment

Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad

Zydus supplies first consignment of its Covid-19 vaccine ZyCoV-D
News | February 02, 2022

Zydus supplies first consignment of its Covid-19 vaccine ZyCoV-D

The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST

Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin
Biotech | November 05, 2021

Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin

The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent

Latest Stories

QMS Medical Allied Services posts 134.36% jump in consolidated PAT in Q4 FY25

Paras Health Gurugram raises alarm over surge in tobacco-related cancers

Pfizer’s Braftovi combination regime reduces death risk for patients with BRAF V600E mutant mCRC

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging